Introduction
============

Best vitelliform macular dystrophy (BVMD), also known as Best disease, is a dominant, bilateral, symmetric, progressive disease of the macular area; patients present with symptoms of metamorphopsia, blurred vision and a decrease in central vision ([@b1-mmr-16-04-4751],[@b2-mmr-16-04-4751]). BVMD usually has an early onset, often in the first decade of life ([@b3-mmr-16-04-4751],[@b4-mmr-16-04-4751]); however, there are some atypical types of BVMD ([@b2-mmr-16-04-4751]). It is the second most common form of juvenile macular degeneration and accounts for about 1% of all cases of macular degeneration ([@b5-mmr-16-04-4751]). At present, it remains an inherited macular dystrophy with no effective treatment.

There are five stages of BVMD that have been described based on fundus presentation: i) Stage 1 (previtelliform stage), which presents normal macula or subtle retinal pigment epithelium (RPE) alterations; ii) Stage 2 (vitelliform stage), in which the macula exhibits a typical well-circumscribed 0.5-to 2-disc-diameter 'egg-yolk' lesion; iii) Stage 3 (pseudohypopyon stage), in which yellow material accumulates inferiorly to the retina; iv) Stage 4 (vitelliruptive stage), which has a 'scrambled-egg' lesion and partial resorption of the material; and v) Stage 5 (atrophic stage), final macular atrophy that is similar to other macular diseases ([@b6-mmr-16-04-4751],[@b7-mmr-16-04-4751]). In addition, BVMD may present with or without choroidal neovascularization ([@b8-mmr-16-04-4751]--[@b10-mmr-16-04-4751]).

BVMD is associated with mutations in bestrophin-1 (*BEST1*; formerly known as the *VMD2*) ([@b11-mmr-16-04-4751]), which has been mapped to chromosome 11q12-q13. It is 15 kb in length and contains 11 exons of which 10 are protein-coding ([@b10-mmr-16-04-4751]). At least 269 *BEST1* mutations have been reported in BVMD with clinically distinguishable degenerative eye diseases ([@b12-mmr-16-04-4751],[@b13-mmr-16-04-4751]). The bestrophin-1 protein is 68 kDa and contains a highly conserved N-terminal domain that includes several putative transmembrane regions, and a C-terminal domain that is highly variable ([@b10-mmr-16-04-4751],[@b14-mmr-16-04-4751]). Bestrophin-1 is expressed in the basolateral plasma membrane of the RPE and functions as a calcium-activated chloride channel ([@b12-mmr-16-04-4751],[@b15-mmr-16-04-4751]). Notably, bestrophin-1 can form a multimer through interaction of the N-terminal and C-terminal domains, which is important for its normal function ([@b14-mmr-16-04-4751],[@b16-mmr-16-04-4751]). Currently, the pathogenesis of BVMD is still unclear. Identification of *BEST1* mutations is the first step in unraveling the pathogenesis of BVMD and may aid genetic counseling. The present study aimed to characterize the clinical presentations of a 10-year old Chinese patient with BVMD and to identify the underlying genetic alterations. The findings from this study expand the mutation spectrum of *BEST1* and will be valuable for genetic counseling and prenatal diagnosis in patients with BVMD.

Patients and methods
====================

The 10-year-old male patient in the present study was from the southern area of China with no known familial history of ocular diseases, and was diagnosed with BVMD on July 2015 at Zhongshan Ophthalmic Center (Guangzhou, China). Ophthalmic examinations were performed as follows. Visual acuity was examined using the Early Treatment Diabetic Retinopathy Study (EDTRS) chart (Precision Vision, Woodstock, IL, USA) ([@b17-mmr-16-04-4751]). Anterior segment photograph was taken using a BX 900 slit lamp (Haag-Streit AG, Koeniz, Switzerland). Anterior segment measurements were performed with Pentacam HR version 70700 (Oculus Optikgeräte GmbH, Wetzlar, Germany). Optical Coherence Tomography (OCT) was performed with a Cirrus HD-OCT (Carl Zeiss AG, Oberkochen, Germany). Fundus photography and fundus fluorescein angiography (FFA) imaging were performed using a Heidelberg Retina Angiograph (Heidelberg Engineering GmbH, Heidelberg, Germany) ([@b18-mmr-16-04-4751]--[@b20-mmr-16-04-4751]). Briefly, fluorescein was injected intravenously and stimulated by blue light at a wave length of 465--490 nm. After injection, fluorescein first appeared in the optic nerve and choroid within 8--12 sec (choroidal phase), and then in the arteries 1--3 sec later. Following complete filling of the arteries, the dye began to fill the veins (arteriovenous phase). Following complete filling of the veins (venous phase), roughly 1 min after injection, the fluorescence began to decrease (recirculation phase). Physical examinations were performed and systemic diseases were excluded.

A total of 200 subjects from the same population without BVMD as well as the unaffected family members of this patient were recruited between March and September, 2015 as controls. Prior to collection of venous blood samples, written informed consent was obtained from all the participating individuals, according to the principles of the Declaration of Helsinki. A total amount of 1 ml of blood sample was collected from each subject, lysed by red blood cell lysis buffer, and centrifuged at 2,000 × g for 5 min at room temperature. Genomic DNA was extracted from peripheral blood leucocytes using a DNA extraction kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s protocol ([@b21-mmr-16-04-4751]--[@b24-mmr-16-04-4751]).

For mutation detection, exons of the *BEST1* gene were amplified by polymerase chain reaction (PCR). The sequences for the forward and reverse primers for PCR were listed in [Table I](#tI-mmr-16-04-4751){ref-type="table"}. PCR was conducted in 50 µl reactions and the cycling profile included: Initial denaturation at 94°C for 5 min, followed by 40 cycles of 94°C for 45 sec, 59°C for 45 sec, 72°C for 45 sec and a final extension at 72°C for 10 min. All reagents in the PCR reaction were obtained from the PCR amplification kit (Takara Bio, Inc., Otsu, Japan) and used according to the manufacturer\'s protocols. The PCR products were visualized on a 1% agarose gel with ethidium bromide staining. After recycling the DNA from the gel using the DNA extraction kit (Takara Bio, Inc.), 20 µl PCR product of each subject with a concentration of 100 ng/µl was sequenced by Sanger sequencing method from both directions with an ABI3730 Automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The sequencing primers were the same as the PCR primers ([Table I](#tI-mmr-16-04-4751){ref-type="table"}). The sequencing results were analyzed using the SeqManII program of the Lasergene package (DNAStar, Madison, WI, USA), and were compared with the reference sequences (NC_000011.10) obtained from the National Center for Biotechnology Information database.

Results
=======

Refractive error was +6.25 diopter sphere in both eyes with best-corrected visual acuity of 0.2 in the right eye and 0.1 in the left eye; the cornea and the lens were transparent. Fundus examination revealed vitelliruptive lesions with an 'egg-yolk' appearance in both eyes ([Fig. 1](#f1-mmr-16-04-4751){ref-type="fig"}, white arrowheads). Fluorescein angiography was normal in the early detection period (within 1 min of fluorescein injection, [Fig. 2A and B](#f2-mmr-16-04-4751){ref-type="fig"}) and there was a small amount of hyperfluorescence of the angiographic sequence with moderate leakage at the late detection period (after 10 mins of fluorescein injection, [Fig. 2C and D](#f2-mmr-16-04-4751){ref-type="fig"}, white arrowheads) in both eyes.

OCT scans revealed that the foveal region of both eyes was abnormally thick due to neuroretinal detachment from the RPE ([Fig. 3](#f3-mmr-16-04-4751){ref-type="fig"}), which was probably triggered by the abnormal accumulation of hyper-reflective materials beneath the retina of both eyes.

Sequence analysis identified two heterozygous genetic variations in this patient: c.292G\>A (p.Glu98Lys) in exon 4 and c.1608C\>T (p.Thr536Thr) in exon 10, ([Fig. 4](#f4-mmr-16-04-4751){ref-type="fig"}). Neither of these variations were identified in the unaffected family members or normal controls from the same population. The c.1608C\>T (p.Thr536Thr) mutation in *BEST1* is a previously identified single nucleotide polymorphisms (SNP) ([@b4-mmr-16-04-4751]), whereas c.292G\>A (p.Glu98Lys) is a novel mutation.

Discussion
==========

BVMD is an autosomal dominant disease characterized by egg yolk-like lesions in the macula ([@b5-mmr-16-04-4751]). During the early stages of the disease, patients with BVMD present with abnormal depositions of lipofuscin-like material at the RPE layer that classically resembles an egg yolk ([@b16-mmr-16-04-4751],[@b25-mmr-16-04-4751]). In the present study, a 10-year-old patient was in early stage 2 of BVMD. Accumulation of lipofuscin-like material in the RPE was observed, although his visual acuity was normal. As pathology of the disease progresses, vision loss may occur if RPE disorganization eventually undermines the overlying photoreceptors. Patients may also exhibit multiple extramacular lesions, hemorrhage, macular holes, or glaucoma ([@b7-mmr-16-04-4751],[@b26-mmr-16-04-4751],[@b27-mmr-16-04-4751]). It should be noted that the patient in the present study exhibited high hyperopia at the age of 10, which was similar to the reports of other studies of BVMD patients ([@b7-mmr-16-04-4751],[@b27-mmr-16-04-4751]).

BVMD is associated with mutations in the *BEST1* gene. To date, a total number of 269 unique *BEST1* DNA variants have been identified and are listed in the Regensburg University database (<http://www-huge.uni-regensburg.de/BEST1_database/>). An overview of the distribution of the known distinct exonic mutations is provided in the [Fig. 5](#f5-mmr-16-04-4751){ref-type="fig"}; these data appear to indicate that exons 2, 4 and 8 are hot spots in the *BEST1* gene, as \>30 mutations have been reported among these exons so far. Consistently, the c.292G\>A (p.Glu98Lys) mutation identified in the present study is also located in exon 4. The c.1608C\>T (p.Thr536Thr) mutation identified in this patient is a known SNP. Various other SNPs have been identified in the *BEST1* gene, including c.87C\>T (p.Tyr29Tyr) and c.109T\>C (p.Leu37Leu) in exon 2, c.219C\>A (p.Ile73Ile) in exon 3, and c.1410G\>A (p.Thr470Thr), c.1557C\>T (p.Ser519Ser) and c.1608T\>C (p.Thr536Thr) in exon 10 ([@b4-mmr-16-04-4751],[@b28-mmr-16-04-4751]). The cellular function of the bestrophin-1 has not been fully elucidated. Therefore, it remains challenging to predict which mutations may be pathological.

Many of the disease-causing mutations in *BEST1* are dominant negative and affect the chloride channel function of the protein ([@b29-mmr-16-04-4751]). These mutations cause amino acid alterations in the highly acidic region of the C-terminus, disrupt the interaction between the N- and the C-terminal domains and may interfere with the formation of the bestrophin multimer ([@b16-mmr-16-04-4751]). A previous study reported that patients with BVMD may have two possible disease-causing variations in *BEST1*, neither of which causes macular disease alone ([@b11-mmr-16-04-4751]). It remains unclear how the two mutations act in unison and affect protein function; it is possible that multiple allele abnormalities may be required for the pathogenesis of the disease. Understanding the underlying mechanisms of how *BEST1* mutations cause clinical presentation and the characterization of BVMD may greatly improve the diagnosis and treatment of these patients in the future.

A limitation of the present study is that only one patient with BVMD was examined. Future studies are required to investigate independent cohorts of patients affected by BVMD and to characterize the association between different mutations and clinical phenotypes.

In conclusion, the present study identified one novel mutation and one SNP in *BEST1* in a Chinese patient with BVMD. These findings expand the mutation spectrum of *BEST1* and will be valuable for genetic counseling and prenatal diagnosis in patients with BVMD.
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![Fundus examination of both eyes. Fundus examination demonstrated abnormal depositions of lipofuscin-like material at the level of the RPE. The classical yellow lesion had an egg yolk appearance (white arrowheads). Magnification \~x2.5. OD, oculus dexter (right eye); OS, oculus sinister (left eye).](MMR-16-04-4751-g00){#f1-mmr-16-04-4751}

![FFA examination of both eyes. (A and B) At the early stage of the angiographic sequence, FFA was normal in both eyes. (C and D) At the late stage of the angiographic sequence, a low amount of hyperfluorescence was observed and was associated with moderate leakage in both eyes (white arrowheads). Magnification \~x2.5. FFA, fundus fluorescein angiography; OD, oculus dexter (right eye); OS, oculus sinister (left eye).](MMR-16-04-4751-g01){#f2-mmr-16-04-4751}

![OCT scans of both eyes. The OCT scan printout bears a pseudo-color imaging and retinal mapping is based on different color codes (white, red, orange, yellow, green, blue, and black in order); white being the thickest (High reflectivity, \>470 µm) and black being the thinnest (low reflectivity, \<150 µm). Green color indicates intermediate reflectivity. OCT scans revealed that the foveal regions of both eyes were abnormally thick due to neuroretinal detachment from the RPE, which was possibly caused by abnormal accumulation of hyperreflective materials beneath the retina. OCT, optical coherence tomography; RPE, retinal pigment epithelium; OD, oculus dexter (right eye); OS, oculus sinister (left eye).](MMR-16-04-4751-g02){#f3-mmr-16-04-4751}

![Sequence analysis of this patient and controls. Two heterozygous mutations, including c.292G\>A (p.Glu98Lys) in exon 4 and c.1608C\>T (p.Thr536Thr) in exon 10, were identified in the BVMD patient, but not in any of the unaffected family members or the normal controls in the same population. BVMD, Best vitelliform macular dystrophy.](MMR-16-04-4751-g03){#f4-mmr-16-04-4751}

![Distribution of the known distinct mutations identified in the *BEST1* gene.](MMR-16-04-4751-g04){#f5-mmr-16-04-4751}

###### 

Primers for amplification of *Best1* exons.

  Exon    Forward (5′-3′)           Reverse (5′-3′)               Product size (bp)   Annealing temperature (°C)
  ------- ------------------------- ----------------------------- ------------------- ----------------------------
  *2*     AGTCTCAGCCATCTCCTCGC      TGGCCTGTCTGGAGCCTG            212                 61
  *3*     GGGACAGTCTCAGCC ATCTC     CAGCTCCTCGTGATCCTCC           238                 58
  *4*     AGAAAGCTGGAGGAGCCG        GCGGCAGCCCTGTCTGTAC           1408                59
  *5*     GGGGCAGGTGGTGTTCAGA       GGCAGCCTCACCAGCCTAG           150                 59
  *6*     GGGCAGGTGGTGTTCAGA        CCTTGGTCCTTCTAGCCTCAG         181                 59
  *7*     CATCCTGATTTCAGGGTTCC      CTCTGGCCATGCCTCCAG            257                 59
  *8*     AGCTGAGGTTTAAAGGGGGA      TCTCTTTGGGTCCACTTTGG          215                 59
  *9*     ACATACAAGGTCCTGCCTGG      GCATTAACTAGTGCTATTCTAAGTTCC   298                 59
  *10A*   GGTGTTGGTCCTTTGTCCAC      CTCTGGCATATCCGTCAGGT          591                 59
  *10B*   CTTCAAGTCTGCCCCACTGT      TAGGCTCAGAGCAAGGGAAG          457                 59
  *11*    CATTTTGGTATTTGAAATGAAGG   CCATTTGATTCAGGCTGTTG          216                 59

[^1]: Contributed equally
